Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug containing four active pharmaceutical ingredients: tinidazole, fluconazole, metronidazole, and clotrimazole. All are anti-infective agents but with different mechanisms of action and antimicrobial spectra. Tinidazole and metronidazole are nitroimidazoles effective against anaerobic bacteria and protozoa by damaging microbial DNA. Fluconazole is a triazole antifungal that inhibits fungal ergosterol synthesis, disrupting cell membrane formation. Clotrimazole is an imidazole antifungal that also inhibits ergosterol synthesis in fungi but is typically used topically or intravaginally. This combination would theoretically provide broad-spectrum coverage for mixed vaginal infections (bacterial vaginosis, trichomoniasis, vulvovaginal candidiasis), targeting both bacterial and fungal pathogens simultaneously. While combinations of two or three of these agents (e.g., tinidazole + fluconazole; metronidazole + clotrimazole) are documented in clinical use for syndromic management of vaginal discharge[1][3][6], there is no evidence from the provided sources or standard references for a marketed product containing all four together as a single formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tinidazole + fluconazole + metronidazole + clotrimazole.